The total return over the past 12 months is -83.69% vs. +16.94% for the S&P 500. So far it's up -72.32% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (83.69%) | (38.91%) | (44.50%) | (39.47%) | N/A | N/A |
| Total Return CAGR | (83.69%) | (38.91%) | (44.50%) | (39.47%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Atossa Therapeutics, Inc. (ATOS)
| Year | Start price | End price | ATOS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $8.85 | $2.45 | (72.32%) | +14.51% | (86.83%) |
| 2025 | $14.16 | $8.85 | (37.50%) | +17.72% | (55.22%) |
| 2024 | $13.20 | $14.16 | +7.27% | +24.89% | (17.62%) |
| 2023 | $7.95 | $13.20 | +66.04% | +26.19% | +39.85% |
| 2022 | $24.00 | $7.95 | (66.87%) | (18.17%) | (48.70%) |
| 2021 | $14.25 | $24.00 | +68.42% | +28.74% | +39.68% |
| 2020 | $23.55 | $14.25 | (39.49%) | +18.37% | (57.86%) |
| 2019 | $15.30 | $23.55 | +53.92% | +31.22% | +22.70% |
| 2018 | $46.80 | $15.30 | (67.31%) | (4.56%) | (62.75%) |
| 2017 | $253.80 | $46.80 | (81.56%) | +21.70% | (103.26%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
